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Discoveries made in the last five years or so have shown that we are introduced to micro-organisms even before our birth. Contrary to earlier belief that the mother’s womb protects a developing foetus against micro-organisms, we now know that bacteria from the mother’s blood can enter 
the amniotic fluid (that surrounds the developing 
foetus). The type and numbers of these bacteria have 
a huge bearing not only on pregnancy outcomes but 
also on the immune system of the new-born. Our association with microbes becomes more rapid at the time of our birth. A new-born is exposed to micro-
organisms in almost everything it makes contact with – its mother’s birth canal, skin and breast-milk; other food; and the environment. All its exposed surfaces, 
including its skin, eyes, ears, reproductive tract and 
gut, are quickly colonised by microbes. The nature 
and size of these initial microbial populations can vary 
initially with changes in diet and environment, but as a child grows older, these microbial communities become more stable in composition. The gut of an adult has over thousands of species of micro-
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The gut environment is complex, with different amounts and types of micro-organisms along its length. What role do commensal intestinal micro-organisms have on homeostatic mechanisms in health and development of disease? This article explores some of these emerging frontiers in our understanding of gut bacteria.
organisms of all kinds – bacteria, fungi and viruses, 
and contributes nearly 2 kilograms of her body weight! 
Since Antonie von Leeuwenhoek published his work 
in the early 1700s, scientists have known that micro-organisms are found at various sites in the human 
body, particularly the gut. We’ve also known that not all microbes that are found at a particular location are 
permanent residents; some only appear transiently. Those that are permanent residents establish long-term interactions with their host, forming stable 
populations that may have demonstrable functions. Recent research has begun to demonstrate just how complex some of the interactions between 
Colonisation: This is the process by which microbial 
cells multiply to establish a ‘colony’ after entry into 
the body. Usually, different microbial species abound 
in different parts of the body - bacteria on teeth surface are different than those on the cheek, which in turn differ from those colonising the tongue, etc.  
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microorganisms and their host really are. 
Improvements in laboratory science and (animal) 
model systems are helping us understand some of the 
mechanisms by which human–microbial interactions 
occur, and how they influence health and disease in their human hosts. 
How are intestinal microorganisms 
studied?
Understanding our relationship with intestinal 
micro-organisms depends upon identifying the types and numbers of the different micro-organisms in the gut; and the nature of interactions between different micro-organisms, as well as between micro-organisms and our bodies. The conventional approach to doing this would involve isolating individual microbial species from the gut, and inducing them to reproduce under controlled 
laboratory conditions (popularly called microbial 
culture, or simply ‘culture’). A variety of physico-chemical and biological tests would then be used to 
uniquely identify these colonies, in a process that is 
somewhat similar to identifying human beings based on their facial features. This approach has limited uses, however, because we have not been able to grow the 
many microbes that thrive in the low- (or no-) oxygen 
environment of the human gut under laboratory conditions.In contrast, recent advances in genetics have made it 
possible to identify these micro-organisms by their 
nucleic acids in a process akin to fingerprinting in 
humans. Also, gnotobiotic, knock-out, transgenic and humanized mice models are helping us decipher the cross-talk between gut microbes and their human hosts. 
Thus, information is now emerging not only on ‘who 
is there’ in the gut, but also on ‘what are they doing?’ 
With an improvement of methods to study them, we 
are now able to characterise not just the diversity of microorganisms in the gut, but also their interactions 
and functional stability. 
Microbial communities in the human gut
Much of our early information on colonisation came from studies of aerobic and anaerobic bacteria that could be cultured in labs. These studies have shown 
us that the human gut is differentially colonized, with 
the number and diversity of bacteria in it increasing 
Animal models in characterising gut 
microbiota
Gnotobiotic (from Greek gnostos, known; and bios 
meaning life) refers to a laboratory animal, commonly a mouse, whose microbial composition is known in 
its entirety. These animals are raised in germ-free environments, and then introduced to one or a few species of micro-organisms in a controlled manner 
under laboratory conditions. The effects of this 
specific kind of colonization on the gnotobiotic animal are used to understand similar interactions in humans or other hosts of the microbes.
Knock-out is a laboratory-raised mouse in which a 
specific gene has been inactivated, or ‘knocked out’. Evidence suggests that the genetic background of individuals – the presence/absence of certain genes 
- influences the composition of their gut microbiota. 
Scientists can investigate this by evaluating the effects of knocking-out the mouse counterparts of 
specific human genes on the composition of their gut microbial communities. 
Transgenic is any plant or animal with gene(s) from another organism inserted into its genome. This kind 
of insertion can either happen naturally (for example, genes from disease-causing bacteria found inserted in the DNA of hundreds of varieties of sweet potato), or 
by deliberate human intervention. 
Humanised mice are mice with transplanted human faecal microbiota in their guts. These are compared 
with normal mice to identify the role of intestinal micro-organisms in human metabolism. 
Antonie von Leeuwenhoek: Widely considered to 
be the ‘Father of Microbiology’, Leeuwenhoek was, 
in many ways, an unlikely scientist. A tradesman 
by profession, he had no money, no degree; and 
the only language he knew was his native - Dutch. Despite these disadvantages, he made some of 
the most seminal discoveries in Biology. Grinding 
lenses, he made simple microscopes — 500 of them over his lifetime! He discovered sperm cells, blood cells, bacterial cells on teeth scrapings, as well as microscopic rotifers and protists. 
MicrobiotaThis term refers to the collection of micro-organisms that are found at a particular location, for example, the skin of an individual or an ocean vent.
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that greater microbial richness is associated with 
diets higher in fruits, vegetables and fibre; while lower 
richness is associated with multiple diseases — obesity, 
insulin resistance, dyslipidemia (abnormal amounts of 
lipids in blood) and inflammatory disorders. 
Apart from influencing their composition and/or richness, diets can also alter the metabolic functions of intestinal microbial communities in humans. Intestinal 
bacteria digest many types of food to produce small molecules that are then metabolised in the human liver, 
and have an important role in human physiology. For 
example, carbohydrates in starch can be broken down 
by colonic bacteria to produce short-chain fatty acids, 
which regulate several functions related to immunity 
and lipid synthesis. 
Intestinal microbiota in health and 
diseaseAlthough there are differences between the intestinal microbiota of different individuals, in general more than one microbial species can perform a single metabolic 
function in the human body. This means that in spite 
of differences and changes in the number, type and proportions of individual microbial species, their human hosts can continue to have normal gut function. 
Gut microbiota and the host adapt to each other through 
some very interesting evolutionary and molecular 
processes. One example of this is seen among the 
Japanese. Sushi, a dish made by wrapping rice and raw 
fish in nori (derived from seaweed), is an important part 
of the Japanese diet. Nori is the only food humans eat 
which contains a special class of complex carbohydrates 
called porphyrans. We know of only two organisms with 
enzymes, called porphyranases, capable of breaking 
down porphyrans. One of these is a marine bacterium, called Zobellia galactonivorans, which naturally grows on seaweed. The other is a gut bacterium, called Bacteroides 
plebeius, found only in the intestines of the Japanese. It 
seems likely that this human gut bacterium acquired the 
genes for porphyranases from Zobellia ingested along with the seaweed that forms part of the regular diet of 
the Japanese. By acquiring these genes, gut bacteria are 
able to break down the carbohydrates of the seaweed, 
thus exploiting an additional source of energy. 
progressively. Thus, for every milliliter of its contents, 
the stomach has ~10,000 bacterial cells, the small 
intestine (ileum) has substantially higher density than 
this (~108 bacterial cells/ml), and the distal colon 
houses even greater numbers, ~1013 bacteria/ml. 
To add to this complexity, different bacterial species dominate different locations of the gut, with Helicobacter spp. found in the stomach, facultative anaerobes and 
strict anaerobes in the ileum, and predominantly anaerobic bacteria in the distal colon. What’s more – the composition of microbial communities in the human gut 
can vary over the lifetime of an individual and up to as 
much as 30% between individuals.Based on the composition of their gut microbiota, a 
research study in 2011 classified all humans into three 
categories or ‘entero’-types. Humans belonging to the 
first category, and called Type I entero-types, have high levels of Bacteroides species, and thus also of 
the enzymes for synthesis of biotin (Vitamin B7) that 
these bacteria produce. Type 2 entero-types have less 
Bacteroides spp. but more Prevotella spp., and, therefore, 
more enzymes for thiamine (vitamin B1); while Type 3 have high levels of Ruminococcus spp. 
Diet and the intestinal microbiota: you 
are what you eatThe relationship between intestinal microbiota and their 
host is strongly influenced by the diet of the host. 
By acting as substrates for microbial metabolism, 
the nutrients we consume play an important role in altering the structure of microbial communities in the 
gut. One example of this is seen in the fact that when compared to formula-fed infants, breastfed ones show 
higher levels of bifidobacteria. Bifidobacteria have 
multiple health-related benefits in a newborn, such as the protection of the gut mucosa, increased production 
of immunoglobulin A, and the ability to metabolise 
carbohydrates in breast milk.  
Similarly, another study compared the intestinal 
microbiota of children in rural Burkina Faso in Africa, with children in Europe. While the diet of the African 
children was rich in complex carbohydrates, fibre and non-animal protein, that of their European counterparts was rich in animal protein, sugar, starch and fat. This 
study showed that children in Burkina Faso had greater microbial richness, more Prevotella and less Bacteroides, 
and produced higher levels of short-chain fatty acids 
than children in Europe. Other studies have shown 
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Figure 1. An electron micrograph of a cluster of E. coli, magnified 
10,000 times. Source: Photo by Eric Erbe, digital colorization by 
Christopher Pooley, both of USDA, ARS, EMU, Wikimedia Commons. 
License: Public Domain. URL: https://en.wikipedia.org/wiki/File:E_coli_
at_10000x,_original.jpg
to maintain their body weight. This indicates that gut microbes help us derive the maximum nutritional value from available nutrients.  
Several studies link gut microbiota to obesity and malnutrition. In one of these studies, germ-free mice 
put on weight when they were transplanted with gut microbes from an obese person, but not those from a thin person. It was also possible to use the gut microbiota from a thin person to displace the microbiota of obese 
mice. As long as they were put on a healthy diet, this transplantation could prevent the obese mice from 
gaining weight.  In another study, faecal samples were collected over a long period of time from twins in Malawi, 
a landlocked country in south-eastern Africa that has one 
of the highest infant mortality rates in the world. Results 
from this study, published in 2013, showed that the gut microbiota of children suffering from a severe form of 
malnutrition, called Kwashiorkar, was very different from that of unaffected peers of the same age-group. When the microbiota of the malnourished children was transplanted into gnotobiotic mice fed with Malawian 
diets, they lost weight, and showed an altered amino acid 
and carbohydrate metabolism. A similar study by the same group, conducted in Bangladesh, showed that the 
gut microbiota of malnourished individuals were typically 
like that of much younger individuals, or ‘immature’. 
Symptoms of malnutrition could be reduced slightly 
by therapeutic feeding, with malnourished individuals 
showing temporary maturation of their gut microbiota, 
but soon reverted to their previous ‘malnourished’ state. Studies to explore whether therapeutic food could lead to a more permanent maturation in gut microbiota are 
currently underway.  
With diets that primarily consist of carbohydrates, humans are well-equipped to digest disaccharides, as well as absorb the monosaccharides produced as a 
result. However, our capacity to hydrolyse and utilise 
other complex polysaccharides, particularly those of 
plant origin such as cellulose, xylan and pectin, is limited. 
These carbohydrates can be digested by some anaerobic bacteria that reside in in our distal colon. Equipped 
with specific enzymes for degradation of complex 
polysaccharides, these microbes break down undigested 
dietary carbohydrates to short chain fatty acids that can 
then be utilized by different organs of our body. Thus, 
commensalism or ‘eating together’ helps gut microbial 
communities derive energy from us, while we benefit 
from this association by utilizing otherwise indigestible 
carbohydrates.
Extensive research on the microbiota shows that intestinal bacteria modulate genes involved in several different intestinal functions in humans, including 
nutrient absorption, carbohydrate metabolism and 
intestinal motility.  
Preventing infection: The barrier function 
One of the most significant benefits we derive from resident gut microbiota is that these microbes act as 
a defensive barrier against potential pathogens. They 
do this through a variety of mechanisms, one of which involves the production of antimicrobial substances that are active against several intestinal pathogens. 
For example, Lactobacillus and Bifidobacterium spp. produce antibacterial substances active against a wide range of pathogens including entero-pathogenic E. coli, and Listeria monocytogenes, etc. Other mechanisms 
used by gut bacteria to prevent pathogen colonization 
include impairment of flagellar motility and prevention of cellular damage in the host. 
Nutrient uptake
One of the most exciting findings about the host-microbe 
relationship in recent years has been the role of the intestinal microbiota in malnutrition. 
The relationship between the microbial flora of the gut 
and the host depends on the capability of either or both partners to utilize nutrients in human diets. Does this 
mean that gut microbes actively compete with us for 
nutrients from our food? On the contrary, experiments comparing the calorie intake of conventional and germ-
free mice show that the former require 30% less calories 
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Disease states and the microbiotaWhile several studies have shown that a new-born’s 
immune system co-evolves with the microbial community 
in her gut, gut microbiota may also contribute to some 
diseases, like atherosclerosis (or a hardening of arteries), 
by breaking down dietary lipids to harmful metabolites. 
Similarly, gut microbes have been shown to break 
down another dietary component – choline, to produce 
trimethylamine oxide, a small molecule that is strongly 
associated with an increased risk for coronary vascular disease in humans. There is evidence that the gut microbiota also contributes to several forms of liver disease including 
non-alcoholic fatty liver disease, alcoholic and auto-immune liver disease. Similar associations between altered gut microbiota and disease states are also found 
in inflammatory bowel disease, diabetes and colon 
cancer. The mechanisms by which gut microbes cause these different diseases are still being investigated. 
Using microbiota for treatment - faecal microbe 
transplants
While they can contribute to diseases in the host, gut microbes can also be used to cure certain ailments.
Clostridium difficile is an anaerobic bacterium that 
is commonly found in the gut. However, the use of 
antibiotics or a severe inflammation of the large bowel in hospitalised patients can lead to an overgrowth of C. 
difficile. This can result in severe diarrhoea (up to 15 
times a day), abdominal pain, weight loss, fever, and even be fatal. Even when treatment with antibiotics is 
initially successful, the infection can recur. This is believed 
to be due to the inability of the intestinal microbiota to suppress the growth of the toxin-producing C. difficile. 
Recently, Faecal Microbiota Transplant (FMT) has begun to be used to treat this recurrent condition with some 
success. FMT is a procedure in which faecal matter, or stool, is collected from a tested donor, mixed with a saline solution, and placed in a patient’s gut through an enema 
or an endoscopy. Faecal transplants have also had good results with other digestive or auto-immune diseases, 
including Irritable Bowel Syndrome and  inflammatory bowel disorders. 
ConclusionIn the past decade, there has been increasing interest in the human microbiota, and new methods and tools are being developed to enable more detailed studies. 
One important reason for this interest has been the recognition that the commensal microorganisms comprising human microbiota are more than just 
passengers in the host, and may actually regulate certain vital host functions. With a better understanding of the 
contribution of intestinal microbiota to specific disease 
states, it may be possible to develop new strategies or drugs to modulate these microbes to treat or prevent diseases. 
Gagandeep Kang is a Professor at the Christian Medical College, Vellore. She has studied enteric infections for over 20 years, and finds that 
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Figure 2. Scanning electron micrograph of Clostridium difficile from 
a stool sample. Source: CDC/ Lois S. Wiggs (PHIL #6260), 2004, Obtained 
from the CDC Public Health Image Library, Wikimedia Commons. License: 
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